PDCD1 and liver cancer: The enhanced immune function of PBMCs in HBV+ ESCC patients after anti-PD-1 therapy suggested that there is a stronger immunosuppressive microenvironment in HBV+ non-liver cancer patients before anti-PD-1 therapy.